Tino F. Schwarz
Wuerzburg, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 75 publications
STIKO Recommendation: MF59-Adjuvanted Influenza Vaccine for Individuals ≥ 60 Years of Age
Journal: Deutsche medizinische Wochenschrift (1946)
Published: May 04, 2026
Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial.
Journal: Human vaccines & immunotherapeutics
Published: November 06, 2025
Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18-49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 15, 2025
Safety and Immunogenicity of 1 or 2 Additional Doses of the Adjuvanted Recombinant Zoster Vaccine Administered 5-6 Years After Primary Vaccination in Adults ≥50 Years.
Journal: Open forum infectious diseases
Published: September 26, 2025
Virus-like particles: a versatile and effective vaccine platform.
Journal: Expert review of vaccines
Published: May 19, 2025
Enhanced influenza vaccination for older adults in Europe: a review of the current situation and expert recommendations for the future.
Journal: Expert review of vaccines
Published: May 01, 2025
Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications.
Journal: EClinicalMedicine
Published: January 08, 2025
Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial.
Journal: The Lancet. Respiratory medicine
Published: November 05, 2024
Cell-based influenza vaccines: An effective vaccine option for under 60-year-olds.
Journal: GMS hygiene and infection control
Published: May 20, 2024
Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: February 29, 2024
Cell-based influenza vaccines: an effective vaccine option for under 60-year-olds
Journal: Wiener klinische Wochenschrift
Published: January 10, 2024
Last Updated: 09/26/2026